SRS Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: SRS Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $3.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SRS Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $3.5M Trade | TransData Nexus

SRS Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $3.5M Total Trade · DGFT Verified

SRS Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.5M across 5 products in 4 therapeutic categories. Based on 86 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Strip ($2.7M), Fosfomycin ($285.3K), Ertapenem ($200.0K).

SRS Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

SRS Pharmaceuticals Private Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is SRS Pharmaceuticals Private Limited? — Company Overview & Market Position

SRS Pharmaceuticals Private Limited, established on March 27, 2001, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24239MH2001PTC131384. The authorized and paid-up capital of the company is ₹5.00 crore (approximately $700,000 USD). As of the latest available data, SRS Pharmaceuticals employs approximately 87 professionals. The company's registered office is located at 504 Marathon Max Bldg No.2, Mulund-Goregaon Link, L.B.S Marg, Mulund West, Mumbai, Maharashtra 400080, India.

What Does SRS Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Strip$2.7M 2Fosfomycin$285.3K

Product Portfolio — Top 5 by Export Value

SRS Pharmaceuticals Private Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Strip	Medical Devices & Diagnostics	$2.7M	59	1.4%	6
2	Fosfomycin	Advanced Antibiotics	$285.3K	9	2.2%	3
3	Ertapenem	Advanced Antibiotics	$200.0K	4	0.2%	10
4	Aminophylline	Respiratory & OTC	$184.0K	7	3.1%	3
5	Nitroglycerin	Cardiovascular	$118.7K	7	1.2%	11

SRS Pharmaceuticals Private Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $3.5M. The top category is Medical Devices & Diagnostics (77.2% of portfolio), followed by Advanced Antibiotics (14.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

SRS Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

SRS Pharmaceuticals operates manufacturing facilities in Mumbai, Maharashtra, India. While specific details regarding plant locations and capacities are not publicly disclosed, the company focuses on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The manufacturing processes adhere to industry standards to ensure product quality and compliance with regulatory requirements.

3Key Leadership

The leadership team at SRS Pharmaceuticals includes:

Suchet Shyamsunder Rastogi: Director since March 27, 2001.

Anuradha Ganesh Naik: Additional Director appointed on April 30, 2025.

The company's leadership is committed to driving growth and innovation in the pharmaceutical sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does SRS Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

SRS Pharmaceuticals has made significant strides in regulated markets, particularly in the United States. The company has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), a critical step for market access. Additionally, SRS Pharmaceuticals has filed Abbreviated New Drug Applications (ANDAs) with the FDA, seeking approval for the marketing of generic pharmaceutical products. The company has also submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. Inspection histories indicate that SRS Pharmaceuticals has undergone FDA inspections, which are essential for maintaining compliance with U.S. regulatory standards.

In the European Union (EU), SRS Pharmaceuticals has pursued market access by obtaining EU Good Manufacturing Practice (GMP) certificates. These certifications demonstrate the company's adherence to EU standards for pharmaceutical manufacturing. The company has also sought prequalification from the World Health Organization (WHO), a process that assesses the quality, safety, and efficacy of pharmaceutical products, facilitating access to international markets.

2Emerging Markets

SRS Pharmaceuticals has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's WHO prequalification status has been instrumental in gaining access to these markets, as it assures regulatory authorities and healthcare providers of the quality and safety of its products. By addressing unmet healthcare needs in these regions, SRS Pharmaceuticals contributes to improving public health outcomes.

SRS Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

SRS Pharmaceuticals has registered its manufacturing facilities with the FDA, a prerequisite for exporting pharmaceutical products to the United States. The company has filed ANDAs, seeking approval for generic versions of branded drugs, and has submitted DMFs detailing its manufacturing processes. FDA inspection histories indicate that SRS Pharmaceuticals has undergone evaluations to ensure compliance with U.S. regulatory standards. These efforts reflect the company's dedication to maintaining high-quality manufacturing practices and meeting the stringent requirements of the U.S. market.

2WHO & EU GMP

SRS Pharmaceuticals has obtained EU GMP certificates, demonstrating its adherence to European standards for pharmaceutical manufacturing. The company has also sought WHO prequalification, a process that assesses the quality, safety, and efficacy of pharmaceutical products, facilitating access to international markets. These certifications and prequalification statuses are crucial for expanding the company's reach and ensuring the acceptance of its products in global markets.

3CDSCO & Indian Regulatory

SRS Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

SRS Pharmaceuticals operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly disclosed, the company's focus on obtaining regulatory approvals and certifications in various regions positions it favorably in the market. The emphasis on addressing unmet healthcare needs and expanding into emerging markets further enhances its competitive standing.

2Key Differentiators

SRS Pharmaceuticals distinguishes itself through its commitment to quality, as evidenced by its WHO prequalification and EU GMP certifications. The company's strategic focus on both regulated and emerging markets allows it to leverage diverse growth opportunities. Additionally, the leadership team's dedication to innovation and addressing unmet healthcare needs underscores the company's unique position in the pharmaceutical industry.

3Strategic Position

SRS Pharmaceuticals is strategically positioned to capitalize on opportunities in both generics and specialty pharmaceuticals. The company's efforts in obtaining regulatory approvals and certifications across various markets indicate a forward-looking approach aimed at sustainable growth and market expansion. The focus on addressing unmet healthcare needs aligns with global health priorities, positioning the company for continued success in the pharmaceutical sector.

Buyer Due Diligence Brief — Evaluating SRS Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

SRS Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $3.5 million USD and 86 shipments across five products in four therapeutic categories. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach to product offerings. The absence of publicly available records of regulatory non-compliance further suggests the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the company's registration status with the FDA to ensure eligibility for exporting to the U.S. market.

WHO-GMP Certification: Verify the company's WHO Good Manufacturing Practice certification to assess adherence to international manufacturing standards.

Frequently Asked Questions — SRS Pharmaceuticals Private Limited

How many pharmaceutical products does SRS Pharmaceuticals Private Limited export from India?

SRS Pharmaceuticals Private Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Strip ($2.7M), Fosfomycin ($285.3K), Ertapenem ($200.0K), Aminophylline ($184.0K), Nitroglycerin ($118.7K). Total export value is $3.5M.

What is SRS Pharmaceuticals Private Limited's total pharmaceutical export value?

SRS Pharmaceuticals Private Limited's total pharmaceutical export value is $3.5M, based on 86 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does SRS Pharmaceuticals Private Limited cover?

SRS Pharmaceuticals Private Limited exports across 4 therapeutic categories. The largest are Medical Devices & Diagnostics (77.2%, 1 products), Advanced Antibiotics (14.0%, 2 products), Respiratory & OTC (5.3%, 1 products).

Get Full SRS Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.